The three largest GI endoscopy companies in the U.S. in 2026 are Exact Sciences (now part of Abbott), Boston Scientific and Olympus.
That ranking comes from iData Research market share data for the U.S. gastrointestinal endoscopic device market in 2025.
Abbott completed its acquisition of Exact Sciences in March 2026, which puts the top spot under a new owner.
iData Research valued the U.S. market at nearly $7.6 billion in 2025.
This guide explains who leads, what each company sells and why a stool-based screening test sits at the top of an endoscopy ranking.
Find growth niches in minutes, not months.
Explore quick, actionable insights from the select markets.
Table of Contents
➜ Who are the top GI endoscopy companies in 2026
➜ Why Abbott and Exact Sciences lead the U.S. GI market
➜ What makes Boston Scientific a top GI endoscopy company
➜ Why Olympus still leads in GI endoscopes
➜ How big is the U.S. GI endoscopy market
➜ What else changed in GI endoscopy this year
Key Takeaways
- Exact Sciences led the U.S. GI endoscopic device market in 2025, driven by its Cologuard FIT-DNA test.
- Abbott completed its acquisition of Exact Sciences in March 2026, making Exact Sciences a wholly owned subsidiary.
- Boston Scientific ranked second and led more market segments than any other company.
- Olympus ranked third in the U.S. and led the GI endoscope and ESD knife segments.
- iData Research expects the U.S. market to grow from nearly $7.6 billion in 2025 to $10.9 billion, a CAGR of 5.6%.
Who are the top GI endoscopy companies in 2026
The top three GI endoscopy companies in the U.S. are Exact Sciences, Boston Scientific and Olympus.
Exact Sciences ranked first, and it now operates as a wholly owned subsidiary of Abbott.
Boston Scientific ranked second on the strength of its stents, ERCP devices and hemostasis tools.
Olympus ranked third, led by its GI endoscopes.
These positions reflect 2025 market share data from the iData Research U.S. Gastrointestinal Endoscopic Devices Market report.
Why Abbott and Exact Sciences lead the U.S. GI market
Exact Sciences was the leading competitor in the total U.S. GI market in 2025, according to iData Research.
Its lead comes mainly from continued adoption of Cologuard, its FIT-DNA test for colorectal cancer screening.
iData Research counts FIT-DNA tests in the U.S. GI market alongside scopes, stents, biopsy tools and other endoscopic devices.
Exact Sciences added to its position with Cologuard Plus, its next-generation stool-based test, launched after FDA approval in 2024.
On March 23, 2026, Abbott announced it had completed its acquisition of Exact Sciences.
Abbott says the deal makes it a leader in U.S. cancer screening and precision oncology diagnostics.
Screening is also what ties a stool test to endoscopy.
The CDC notes that the FIT-DNA test is done once every three years, and a positive result needs a colonoscopy to complete screening.
iData Research expects Abbott and Exact Sciences to hold a strong position as FIT-DNA adoption grows with wider screening eligibility and demand for non-invasive options.
What makes Boston Scientific a top GI endoscopy company
Boston Scientific held the second-leading share of the U.S. GI endoscopic device market in 2025.
It also led more market segments than any other company.
Boston Scientific ranked first in stenting and dilation devices, ERCP devices, and biopsy forceps, polypectomy snares and EUS needles.
It also held the top share in hemostasis devices.
iData Research expects strong growth for its AXIOS lumen-apposing stent.
Its single-use duodenoscope, single-use cholangioscope and single-use choledochoscope lines are expected to grow as well.
In July 2026, Boston Scientific reported Endoscopy segment net sales of $793 million for the second quarter, up 7.6% from $737 million a year earlier.
Why Olympus still leads in GI endoscopes
Olympus ranked third in the U.S. GI endoscopic device market in 2025.
It led the GI endoscope and endoscopic submucosal dissection (ESD) knife segments.
Olympus also competes in capsule endoscopy, ERCP devices, stents, biopsy tools, lifting agents and hemostasis devices.
Outside the U.S., Olympus holds the top share of the global GI endoscopic device market, according to iData Research.
In January 2026, Olympus announced the U.S. launch of the SecureFlex single-use fine needle biopsy device for EUS-guided biopsy.
In February 2026, Olympus reported EAGLE trial results showing its CADDIE AI solution improved detection of high-risk and hard-to-detect colorectal lesions.
In May 2026, Olympus and Canon introduced the Aplio i800 EUS premium ultrasound system in the U.S.
Olympus also formed Swan EndoSurgical with Revival Healthcare Capital in July 2025 to develop an endoluminal robotic system for therapeutic GI procedures.
How big is the U.S. GI endoscopy market
iData Research valued the U.S. GI endoscopic device market at nearly $7.6 billion in 2025.
The market is expected to grow at a CAGR of 5.6% to reach $10.9 billion by 2032.
Growth is supported by expanding colorectal cancer screening eligibility, rising awareness of GI disease, steady procedure demand and new technology.
Hospital consolidation, group purchasing power and reimbursement pressure are expected to keep prices in check.
Staffing and capacity limits at endoscopy facilities may also slow how quickly screening demand turns into procedures.
Follow-up is a real gap, as a CDC-supported study found follow-up colonoscopy completion after abnormal stool tests averaged 47.9% across program sites.
Procedure volume is still climbing, with global colonoscopies projected to reach nearly 107 million in 2026, as covered in our guide to how many colonoscopies are performed each year.
Globally, iData Research valued the GI endoscopic device market at nearly $16.3 billion in 2025, led by Olympus, Boston Scientific and Fujifilm.
What else changed in GI endoscopy this year
Beyond the top three, several other GI endoscopy companies reshaped their portfolios over the past year.
In October 2025, Merit Medical completed its acquisition of Pentax Medical’s C2 CryoBalloon product line for Barrett’s esophagus.
In December 2025, Conmed announced its strategic exit from its gastroenterology product lines.
In March 2026, Micro-Tech Endoscopy agreed to acquire global distribution rights for the Duraclip, Precisor and Optibite lines from CONMED.
That same month, Merit Medical launched the Resilience Through-the-Scope Esophageal Stent.
iData Research also expects single-use endoscopes to keep expanding, especially where reprocessing is complex or infection control is a concern.
Visualization upgrades are moving across the hospital too, as our look at smart laparoscopic visualization shows.
Frequently asked questions about GI endoscopy companies
Who is the number one GI endoscopy company in the U.S.?
Exact Sciences, now owned by Abbott, held the leading share of the U.S. GI endoscopic device market in 2025, according to iData Research.
Did Abbott buy Exact Sciences?
Yes, Abbott completed its acquisition of Exact Sciences in March 2026, making it a wholly owned subsidiary.
Why is Cologuard counted in the GI endoscopy market?
iData Research includes FIT-DNA tests in its U.S. GI market scope because non-invasive screening feeds directly into follow-up colonoscopy.
Which company makes the most GI endoscopes in the U.S.?
Olympus led the U.S. GI endoscope segment in 2025, followed by Boston Scientific and Fujifilm.
How big is the U.S. GI endoscopy market?
The U.S. GI endoscopic device market was valued at nearly $7.6 billion in 2025 and is expected to reach $10.9 billion at a 5.6% CAGR.
Turn market painpoints into opportunities
Explore how procedure trends and competitor positioning create clear openings for industry experts in the market.
